Literature DB >> 7961011

Influence of tumoral, radiobiological, and general factors on local control and survival of a series of 361 tumors of the velotonsillar area treated by exclusive irradiation (external beam irradiation+brachytherapy or brachytherapy alone)

M Pernot1, L Malissard, S Hoffstetter, E Luporsi, P Aletti, D Peiffert, C Allavena, P Kozminski, P Bey.   

Abstract

PURPOSE: To evaluate statistically the factors influencing the therapeutic results. METHODS AND MATERIALS: A statistical study was carried out concerning 361 patients treated from 1977 to 1991 for velotonsillar carcinoma. They received either brachytherapy alone (18) or a combination of external beam irradiation and brachytherapy (343 patients) using an afterloading iridium technique in plastic tubes. The distribution of patients according to the localization was: 128 tonsils, 134 soft palates, 9 posterior pillars, 63 anterior pillars, and 27 glossotonsillar sulcus. The patients were staged as follows: 90 T1, 141 T2, 119 T3, 2 T4, 9 Tx with 230 N0, 93 N1, 9 N2, 20 N3, and 9 Nx.
RESULTS: The results at 5 and 10 years show: local control 80% and 74%, locoregional control 75% and 70%, overall survival 53% and 27%, specific survival 63% and 52%, respectively. The univariate study shows at 5 years a better local control for T1T2 (87%) compared with T3 (67%) with p = 0.00004. The locoregional control is better for N0 (80%) than for N+ (55%) with p = 0.002. This is the same for the overall survival (59% vs. 42%, p = 0.002). Tumors with an extension to the mobile tongue or the base have a poor prognosis (p < 0.002). The radiobiological factors show less recurrences if the total duration of the treatment is < 55 days, the number of days between External Beam Irradiation and brachytherapy is < 20. The security margin seems important also.
CONCLUSIONS: For the combination external irradiation and brachytherapy, the multivariate study for local control shows that ony T, localization, and the total duration of treatment are significant. For complications, classified into four grades, only the dose rate is significant.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961011     DOI: 10.1016/0360-3016(94)90309-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Radiotherapy alone or combined with chemotherapy as definitive treatment for squamous cell carcinoma of the tonsil.

Authors:  William R Kennedy; Michael P Herman; Rohan L Deraniyagala; Robert J Amdur; John W Werning; Peter Dziegielewski; Jessica Kirwan; Christopher G Morris; William M Mendenhall
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-08       Impact factor: 2.503

2.  [Virtual simulation. First clinical results in patients with prostate cancer].

Authors:  A Buchali; S Dinges; S Koswig; P Rosenthal; S Salk; C Harder; L Schlenger; V Budach
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

Review 3.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

4.  Compromised quality of life in adult patients who have received a radiation dose towards the basal part of the brain. A case-control study in long-term survivors from cancer in the head and neck region.

Authors:  Elisabet Löfdahl; Gertrud Berg; Karl-Axel Johansson; Maria Leonsson Zachrisson; Helge Malmgren; Claes Mercke; Erik Olsson; Lena Wiren; Gudmundur Johannsson
Journal:  Radiat Oncol       Date:  2012-10-29       Impact factor: 3.481

5.  Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study.

Authors:  Sanghyuk Song; Hong-Gyun Wu; Chang Geol Lee; Ki Chang Keum; Mi Sun Kim; Yong Chan Ahn; Dongryul Oh; Hyo Jung Park; Sang-Wook Lee; Geumju Park; Sung Ho Moon; Kwan Ho Cho; Yeon-Sil Kim; Yongkyun Won; Young-Taek Oh; Won-Taek Kim; Jae-Uk Jeong
Journal:  BMC Cancer       Date:  2017-08-30       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.